Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ method

Michael Haas, Dirk Waldschmidt, Michael Ståhl, A. Reinacher-Schick, Jens Freiberg‐Richter, Ludwig Fischer von Weikersthal, Florian Kaiser, S Kanzler, Norbert Frickhofen, Thomas Seufferlein, Tobias Dechow, Rolf Mahlberg, Peter Malfertheiner, Gerald Illerhaus, Stefan Kubicka, Andrew Abdulahad, Robert Snijder, Stephan Krüger, C. Benedikt Westphalen, Swantje Held, Michael von Bergwelt‐Baildon, Stefan Boeck, Volker Heinemann